Actively Recruiting
Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0.
Led by University Hospital, Basel, Switzerland · Updated on 2025-07-03
400
Participants Needed
15
Research Sites
781 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of the DISSECTION 2.0 study is to determine whether extended pelvic lymph node dissection (ePLND) provides a therapeutic benefit for high-risk prostate cancer patients by improving cancer staging and potentially removing micrometastatic disease, ultimately improving their outcomes.
CONDITIONS
Official Title
Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older with life expectancy greater than 15 years
- Biopsy-proven prostate cancer with WHO/ISUP grade groups III to V
- High-risk prostate cancer defined as WHO/ISUP grade group III to V or grade group II with PSA over 20 ng/ml
- Negative PSMA-PET scan for regional and distant metastasis
- Multidisciplinary tumor board recommendation for radical prostatectomy
- WHO performance status 0 or 1
- Suitable condition for general anesthesia and radical prostatectomy (ASA score 3 or less)
You will not qualify if you...
- Prostate cancer with ISUP grade group I and clinical stage T1 or T2 by MRI
- Clinical stage T4 prostate cancer by MRI
- Positive PSMA-PET scan for local or distant metastasis
- Prior neoadjuvant, local, or systemic treatment for prostate cancer
- Previous pelvic lymph node dissection or pelvic radiotherapy
- Prior malignancy treated with curative intent less than 2 years before registration unless low risk of recurrence
- Serious medical, psychiatric, psychological, familial, or geographical conditions interfering with treatment or follow-up
- Vulnerable men unable to give informed judgment or under legal guardianship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 15 locations
1
Cantonal Hospital Aarau
Aarau, Switzerland
Actively Recruiting
2
University Hospital Basel
Basel, Switzerland, 4031
Actively Recruiting
3
Inselspital
Bern, Switzerland
Actively Recruiting
4
Lindenhof Hospital
Bern, Switzerland
Actively Recruiting
5
Cantonal Hospital Biel
Biel, Switzerland
Actively Recruiting
6
Cantonal Hospital Chur
Chur, Switzerland
Actively Recruiting
7
University Hospital Geneva
Geneva, Switzerland
Actively Recruiting
8
Centre hospitalier universitaire vaudois (CHUV)
Lausanne, Switzerland
Actively Recruiting
9
Cantonal Hospital Liestal
Liestal, Switzerland, 4410
Actively Recruiting
10
Cantonal Hospital Luzern
Lucerne, Switzerland
Actively Recruiting
11
Ospedale Regionale di Lugano
Lugano, Switzerland
Actively Recruiting
12
Cantonal Hospital Neuchâtel
Neuchâtel, Switzerland
Actively Recruiting
13
Cantonal Hospital St. Gallen
Sankt Gallen, Switzerland
Actively Recruiting
14
Hospital Triemli, Zürich
Zurich, Switzerland
Actively Recruiting
15
University Hospital Zürich
Zurich, Switzerland
Actively Recruiting
Research Team
C
Cyrill Rentsch, Prof. Dr. med.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here